These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18337441)

  • 1. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity.
    Collier K; Schink C; Young AM; How K; Seckl M; Savage P
    J Oncol Pharm Pract; 2008 Mar; 14(1):51-5. PubMed ID: 18337441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersensitivity reactions to etoposide phosphate.
    Sambasivan K; Mahmoud S; Kokache A; Seckl M; Savage P
    J Oncol Pharm Pract; 2014 Apr; 20(2):158-60. PubMed ID: 23740378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide.
    Bernstein BJ; Troner MB
    Pharmacotherapy; 1999 Aug; 19(8):989-91. PubMed ID: 10453971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersensitivity reactions to oxaliplatin in two asian patients.
    Ng CV
    Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
    Fields SZ; Igwemezie LN; Kaul S; Schacter LP; Schilder RJ; Litam PP; Himpler BS; McAleer C; Wright J; Barbhaiya RH
    Clin Cancer Res; 1995 Jan; 1(1):105-11. PubMed ID: 9815892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
    Kaul S; Srinivas NR; Igwemezie LN; Barbhaiya RH
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):15-22. PubMed ID: 8996571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients.
    Kaul S; Srinivas NR; Mummaneni V; Igwemezie LN; Barbhaiya RH
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):23-9. PubMed ID: 8996572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.
    Siderov J; Prasad P; De Boer R; Desai J
    Br J Cancer; 2002 Jan; 86(1):12-3. PubMed ID: 11857004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity.
    Brooks JP; Azmy V; Thompson A; Luon D; Prozora SD; Price C; Hsu FI
    J Oncol Pharm Pract; 2020 Jan; 26(1):228-231. PubMed ID: 30885040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment with Etoposide Base after an Acute Hypersensitivity Reaction to Etoposide Phosphate.
    Leguay Z; Bourneau-Martin D; Pellier I; Le Louet H; Drablier G; Lagarce L; Lainé-Cessac P
    Pediatr Blood Cancer; 2016 Mar; 63(3):571. PubMed ID: 26468691
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypersensitivity and idiosyncratic reactions to oxaliplatin.
    Thomas RR; Quinn MG; Schuler B; Grem JL
    Cancer; 2003 May; 97(9):2301-7. PubMed ID: 12712487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.
    Hudson MM; Weinstein HJ; Donaldson SS; Greenwald C; Kun L; Tarbell NJ; Humphrey WA; Rupp C; Marina NM; Wilimas J
    J Clin Oncol; 1993 Jun; 11(6):1080-4. PubMed ID: 8501494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
    Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
    Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide-induced hypersensitivity reactions. Report of two cases.
    Tucci E; Pirtoli L
    Chemioterapia; 1985 Dec; 4(6):460-2. PubMed ID: 3830414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early studies of etoposide phosphate, a water-soluble prodrug.
    Budman DR
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):8-14. PubMed ID: 8996570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer.
    Soni N; Meropol NJ; Pendyala L; Noel D; Schacter LP; Gunton KE; Creaven PJ
    J Clin Oncol; 1997 Feb; 15(2):766-72. PubMed ID: 9053503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?
    Elligers KT; Davies M; Sanchis D; Ferencz T; Saif MW
    JOP; 2008 Mar; 9(2):197-202. PubMed ID: 18326929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management and preparedness for infusion and hypersensitivity reactions.
    Lenz HJ
    Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
    Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
    J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide phosphate: what, why, where, and how?
    Schacter L
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):1-7. PubMed ID: 8996569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.